Advancell
Latest round
- Series D
Last raised
- Jun 2026
Total raised
- $343M
Investors
- 26
About Advancell
Based in New South Wales, Australia, founded in 2019, Advancell Pty Ltd, also known as AdvanCell, operates as a radiopharmaceutical company. The company was founded by Andrew Adamovich. Currently, Philina Lee is serving as the CEO as of 2026. AdvanCell’s product line includes Alpha 212®, which is a drug that is produced with the help of targeted alpha therapy technology that is used for the treatment of cancer; ²¹²Pb, which is an alpha isotope generator platform that develops therapeutic pipeline clinical programs including ADVC001 (prostate cancer), ADVC001 (melanoma), ADVC003 (pancreatic cancer and breast cancer); and The AdvanCell ²¹²Pb Generator, which is a technology that produces alpha radioligand treatments. AdvanCell is a pre-commercial clinical-stage radiopharmaceutical company, so its revenue is primarily expected to come from a combination of partnership and licensing agreements with pharmaceutical companies, commercial sales of its targeted alpha therapy products (once approved), and manufacturing/isotope supply services built around its proprietary Lead-212 production platform. Public company disclosures emphasize its vertically integrated model, which combines isotope supply, radiopharmaceutical manufacturing, and drug development, suggesting future revenue opportunities from both therapeutic products and supplying/manufacturing radiopharmaceutical materials for internal and partner programs. The company has also highlighted collaborations with major pharmaceutical companies and investments in scalable isotope production and manufacturing infrastructure, indicating that partnership income, milestone payments, and eventual product commercialization are key components of its business model.S. manufacturing capacity.
Who invested in Advancell
26 investors across 3 rounds
See all investors in Advancell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Advancell
Who invested in Advancell?
Advancell has 26 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Advancell raised?
Advancell has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Advancell last raise money?
Advancell's most recent round on record is a Series D, in Jun 2026.
What does Advancell do?
Based in New South Wales, Australia, founded in 2019, Advancell Pty Ltd, also known as AdvanCell, operates as a radiopharmaceutical company.
Where is Advancell headquartered?
Advancell is headquartered in Sydney, Australia.
Which VCs invest in companies like Advancell?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back biotechnology companies at Advancell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Advancell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.